Colombian Cannabis: Showcases a study of the effects of cannabidiol (CBD) on schizophrenia

COLOMBIAN CANNABIS presents a study published in the American Journal of Psychiatry focusing on how cannabidiol (CBD) affects humans and animals suffering from schizophrenia. The study’s results’ suggests that CBD has a positive effect on humans and animals suffering from schizophrenia.

Objective:

Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.

Conclusions:

These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”

 

The full article can be found at: https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2017.17030325

A video of the article can be found at: https://www.youtube.com/watch?v=aT8aaRf9xS0&list=PL9BMKzYDhMNLYAVKgsQpecFBxZaGq98i0

To find more studies about schrizophrenia: http://www.colombiancannabis.co/cannabis-detalle.php?L=S&id=Ng==&p=NA==